SCHEMBL4360100

SCHEMBL4360100

Cc1cccc2c(C3=C(c4cc(N5CCN(C)CC5)c(Cl)cc4F)C(=O)NC3=O)c[nH]c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 17/20 0.57
PRKCH P24723 17/20 0.57
PRKCQ Q04759 17/20 0.57
PRKCD Q05655 17/20 0.57
PRKCB P05771 17/20 0.57
PRKCE Q02156 15/20 0.57
MAP4K1 Q92918 1/20 0.42
JAK3 P52333 2/20 0.41
GSK3B P49841 2/20 0.41
PDPK1 O15530 1/20 0.41
DYRK3 O43781 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
PRKCG P05129 1/20 0.41
FYN P06241 1/20 0.41
CDK1 P06493 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359102 0.86 PRKCH (0.61) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL3555948 0.84 PRKCA (0.60) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL990652 0.80 PRKCA (0.60) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL990596 0.78 PRKCA (0.60) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL989940 0.77 PRKCH (0.61) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL3553175 0.77 PRKCH (0.64) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL990658 0.76 PRKCH (0.62) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL4357973 0.76 PRKCA (0.60) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL991235 0.75 PRKCH (0.61) PRKCAPRKCHPRKCQPRKCDPRKCB
SCHEMBL991238 0.75 PRKCH (0.61) PRKCAPRKCHPRKCQPRKCDPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2009-09-03 US claimed
EP-1747216-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS Novartis Pharma AG. (CH) 2007-01-31 EP claimed
WO-2005113545-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2005-12-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS PRKCA, PRKCB, PRKCE PRKCA 1/4885PRKCH 5/4885PRKCQ 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.